サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1702365

遺伝子検査の世界市場：2025年～2033年

Global Genetic Testing Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
遺伝子検査の世界市場：2025年～2033年
出版日: 2025年04月10日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の遺伝子検査の市場規模は、2024年に147億2,000万米ドルに達し、2033年には542億1,000万米ドルに達すると予測され、2025年～2033年の予測期間中のCAGRは15.4％と見込まれています。

世界の遺伝子検査市場とは、遺伝的状態、遺伝性疾患、将来の健康状態のリスクを特定するためにDNA、RNA、またはタンパク質を分析する診断検査の使用を指します。この市場には、保因者検査、診断検査、予測検査、出生前検査、薬理ゲノミクスなど、さまざまな種類の遺伝子検査が含まれます。これらの検査は、疾患の診断、遺伝的素因の理解、個別化治療戦略の実現に役立ちます。

遺伝子検査は、ヘルスケアを個人の遺伝子プロファイルに合わせて調整し、個別化された治療戦略を可能にします。遺伝子検査は早期診断に役立ち、最適な治療法を特定し副作用を回避することで患者の転帰を改善します。

遺伝性疾患と慢性疾患の有病率の上昇は、遺伝子検査市場の成長を大きく促進すると予想されます。嚢胞性線維症、鎌状赤血球貧血、ハンチントン病などの遺伝性疾患の罹患率が上昇を続ける中、遺伝子検査の需要も伸びています。例えば、嚢胞性線維症財団によると、毎年約1,000例のCFが新たに診断されています。このように毎年増加していることから、早期に診断するための高度な検査方法の需要が高まっています。

遺伝子検査による早期発見は、ヘルスケアプロバイダーが個別化された治療計画を提供するのに役立ち、長期的には転帰を改善し、医療費を削減できる可能性があります。さらに、がん、糖尿病、心血管疾患などの慢性疾患の有病率が上昇していることも、遺伝子検査の必要性をさらに高めています。

慢性疾患を患っている多くの人々が、病気を正確に診断するために遺伝子検査を処方されているか、遺伝子検査に関心を示しています。例えば、2022年のシカゴ大学NORCによると、アメリカ人の17％が実際に遺伝子検査を受けたことがあり、52％がそのような検査に関心があると回答しています。したがって、上記の要因が市場の成長を促進すると予想されます。

遺伝子検査とシーケンシング技術のコストが高いことは、遺伝子検査市場の成長にとって大きな障壁になると予想されます。遺伝子検査の進歩にもかかわらず、次世代シーケンシング（NGS）などのシーケンシング技術に関連する費用は依然として比較的高く、これらの検査を集団の大部分にとって手の届かないものにしています。

この高額な費用は、特に先進国市場と新興国市場の両方において、十分なサービスを受けていない人々の遺伝子検査へのアクセスを制限する可能性があります。例えば、多くの個人は、疾病リスク評価、出生前スクリーニング、個別化医療のための検査を受ける余裕がない可能性があり、これにより、健康転帰を大幅に改善できる早期診断や個別化治療計画が妨げられる可能性があります。

その結果、遺伝子検査やシークエンシング技術の高コストが、アクセシビリティを制限し需要を減少させることで、市場の成長を阻害する可能性が高いです。したがって、上記の要因が世界の遺伝子検査市場の潜在的成長を制限している可能性があります。

当レポートでは、世界の遺伝子検査市場について調査し、市場の概要とともに、製品タイプ別、技術別、検査タイプ別、用途別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界見通し

  • 市場のリーダーとパイオニア
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 遺伝子検査市場（製品タイプ別）

  • 消耗品
  • 装置
  • ソフトウェア

第6章 遺伝子検査市場（技術別）

  • 次世代シーケンシング（NGS）
  • ポリメラーゼ連鎖反応（PCR）
  • 蛍光in situハイブリダイゼーション（FISH検査）
  • その他

第7章 遺伝子検査市場（検査タイプ別）

  • キャリアテスト
  • 出生前検査および新生児検査
  • 着床前検査
  • 予測検査および発症前検査
  • 法医学検査
  • 診断検査
  • その他

第8章 遺伝子検査市場（用途別）

  • がん診断
  • 遺伝性疾患の診断
  • 心血管疾患の診断
  • その他

第9章 遺伝子検査市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • BioRad Laboratories Inc
  • Illumina Inc
  • Myriad Genetics Inc
  • Danaher Corporation
  • Quest Diagnostics Incorporated
  • MedGenome
  • LabCorp
  • 3billion, Inc
  • Blueprint Genetics

第12章 仮定と調査手法

第13章 付録

目次
Product Code: BT226

The global genetic testing market reached US$ 14.72 billion in 2024 and is expected to reach US$ 54.21 billion by 2033, growing at a CAGR of 15.4 % during the forecast period of 2025-2033.

The global genetic testing market refers to the use of diagnostic tests that analyze DNA, RNA, or proteins to identify genetic conditions, hereditary diseases, and the risk of future health conditions. This market includes various types of genetic tests, such as carrier testing, diagnostic testing, predictive testing, prenatal testing, and pharmacogenomics. These tests help in diagnosing diseases, understanding genetic predispositions, and enabling personalized treatment strategies.

Genetic testing allows for personalized treatment strategies, tailoring healthcare to individual genetic profiles. It aids in early diagnosis, improving patient outcomes by identifying the best treatment options and avoiding adverse drug reactions.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Genetic Disorders and Chronic Diseases

The increasing prevalence of genetic disorders and chronic diseases is expected to significantly drive the growth of the genetic testing market. As the incidence of genetic conditions like cystic fibrosis, sickle cell anemia, and Huntington's disease continues to rise, the demand for genetic testing is also growing. For instance, according to the Cystic Fibrosis Foundation, approximately 1,000 new cases of CF are diagnosed each year. This increase in the number every year increases the demand for advanced testing procedures to diagnose the condition at an early stage.

Early detection through genetic testing can help healthcare providers offer personalized treatment plans, potentially improving outcomes and reducing healthcare costs in the long run. In addition, the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is increasing the need for genetic testing even more.

A large number of individuals suffering from chronic diseases are prescribed or are showing interest in genetic testing to diagnose the disease accurately. For instance, according to the NORC at the University of Chicago in 2022, it is stated that 17 percent of Americans have actually undergone genetic testing, and 52 percent report interest in such a test. Thus, the above factors are expected to drive the market growth.

High Cost of Genetic Tests and Sequencing Technologies

The high cost of genetic tests and sequencing technologies is expected to be a significant barrier to the growth of the genetic testing market. Despite advancements in genetic testing, the expenses associated with sequencing technologies, such as next-generation sequencing (NGS), remain relatively high, making these tests unaffordable for a large portion of the population.

This high cost can limit access to genetic testing, particularly for underserved populations in both developed and emerging markets. For example, many individuals may be unable to afford tests for disease risk assessment, prenatal screening, or personalized medicine, which could prevent early diagnosis or personalized treatment plans that could significantly improve health outcomes.

As a result, the high cost of genetic tests and sequencing technologies is likely to hinder the market's growth by limiting accessibility and reducing demand. Thus, the above factors could be limiting the global genetic testing market's potential growth.

Segment Analysis

The global genetic testing market is segmented based on product type, technology, testing type, application, and region.

Technology:

The next-generation sequencing (NGS) segment in technology is expected to dominate the global genetic testing market with the highest market share

Next-Generation Sequencing (NGS) is a transformative technology in the genetic testing market, enabling the rapid and cost-effective sequencing of DNA and RNA. It is widely used in various applications, including clinical diagnostics, oncology, precision medicine, biomarker discovery, and agriculture. The global NGS market is experiencing strong growth, driven by advancements in sequencing technology, decreasing costs, and increasing demand for personalized medicine and genetic research.

For instance, in February 2025, Devyser launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution aimed at improving the accuracy and efficiency of genetic testing for alpha and beta thalassemia. This new version enhances the detection of structural variants and copy number variations (CNVs), providing broader and more precise screening capabilities. This innovation aligns with the growing demand for high-accuracy genetic diagnostics, particularly in the expanding NGS segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global genetic testing market, with the highest market share

North America is expected to dominate the genetic testing market due to various significant factors. The growing prevalence of chronic diseases, and genetic disorders in North America fuels the demand for genetic testing. As more individuals are diagnosed with conditions such as diabetes, cancer, and hereditary diseases, there is a growing demand for genetic testing to help in early diagnosis, risk assessment, and personalized treatment planning.

For instance, according to the report by the American Cancer Society in 2025, it is stated that approximately 1 in 8 women in the United States are diagnosed with breast cancer. Being one of the common cancers among women, the need for genetic testing is expected to increase, which is expected to drive the genetic testing market. Genetic testing detects inherited genetic mutations for various cancers.

Companies in the region are mainly focusing on developing advanced solutions for the diagnosis of genetic diseases to help in identifying the mutations in the genes and help in developing personalized medicine. For instance, in March 2024, Nucleus Genomics, a next-generation genetic testing and analysis company, launched its DNA analysis product aimed at making the benefits of personalized medicine accessible to everyone. This product is designed to empower individuals with the knowledge of their genetic makeup, helping them make informed decisions about their health.

Moreover, North America has one of the highest adoption rates of personalized medicine, where genetic tests play a crucial role in tailoring treatments to individual patients based on their genetic makeup. Thus, various factors are contributing to the region's dominant position in the global genetic testing market.

Competitive Landscape

The major global players in the genetic testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Myriad Genetics Inc., Danaher Corporation, Quest Diagnostics Incorporated, MedGenome, LabCorp, 3billion, Inc., and Blueprint Genetics, among others.

Key Developments

  • In August 2024, Nonacus launched the GALEAS Tumor test, a comprehensive genomic profiling (CGP) solution designed to analyze tumor genetics using next-generation sequencing (NGS). This test integrates bioinformatics and analysis software, making it easier for clinicians to detect genetic mutations linked to various cancers, including rare and complex ones like brain tumors.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global genetic testing market report delivers a detailed analysis with 70 key tables, more than 68 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Testing Type
  • 2.6. Snippet by Application
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Genetic Disorders and Chronic Diseases
      • 3.1.1.2. Advances In Next-Generation Sequencing (NGS) and PCR Technologies
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Genetic Tests and Sequencing Technologies
      • 3.1.2.2. Ethical and Privacy Concerns Regarding Genetic Data
    • 3.1.3. Opportunity
      • 3.1.3.1. Emerging Markets with Untapped Growth Potential
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Genetic Testing Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index By Product Type
  • 5.2. Consumables*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Equipment
  • 5.4. Software

6. Genetic Testing Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index By Technology
  • 6.2. Next-Generation Sequencing (NGS)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Polymerase Chain Reaction (PCR)
  • 6.4. Fluorescence in Situ Hybridization (FISH Test)
  • 6.5. Others

7. Genetic Testing Market, By Testing Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 7.1.2. Market Attractiveness Index By Testing Type
  • 7.2. Carrier Testing*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Prenatal and Newborn Testing
  • 7.4. Preimplantation Testing
  • 7.5. Predictive and presymptomatic testing
  • 7.6. Forensic testing
  • 7.7. Diagnostic Testing
  • 7.8. Others

8. Genetic Testing Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer Diagnosis*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Genetic Disease Diagnosis
  • 8.4. Cardiovascular Disease Diagnosis
  • 8.5. Others

9. Genetic Testing Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

    • 11.1.1. Abbott Laboratories*
    • 11.1.2. Company Overview
    • 11.1.3. Product Portfolio
      • 11.1.3.1. Product Description
      • 11.1.3.2. Product Key Performance Indicators (KPIs)
      • 11.1.3.3. Historic and Forecasted Product Sales
      • 11.1.3.4. Product Sales Volume
    • 11.1.4. Financial Overview
      • 11.1.4.1. Company Revenue
      • 11.1.4.2. Geographical Revenue Shares
      • 11.1.4.3. Revenue Forecasts
    • 11.1.5. Key Developments
      • 11.1.5.1. Mergers & Acquisitions
      • 11.1.5.2. Key Product Development Activities
      • 11.1.5.3. Regulatory Approvals, etc.
    • 11.1.6. SWOT Analysis
  • 11.2. BioRad Laboratories Inc
  • 11.3. Illumina Inc
  • 11.4. Myriad Genetics Inc
  • 11.5. Danaher Corporation
  • 11.6. Quest Diagnostics Incorporated
  • 11.7. MedGenome
  • 11.8. LabCorp
  • 11.9. 3billion, Inc
  • 11.10. Blueprint Genetics

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us